Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
01/08/2026 07:00 AM • Jasper Therapeutics reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of briquilimab for chronic spontaneous urticaria (CSU). The drug demonstrated rapid disease control with 67% of additional BEACON patients achieving complete response at 12 weeks and 75% of CSU participants in the extension study achieving complete response or well-controlled disease. Safety profile remained favorable with low-frequency, predominantly low-grade adverse events. The company plans to initiate a Phase 2b study in the second half of 2026.
JSPR - The company reported strong clinical efficacy data with high response rates (67-75%), favorable safety profile with no dose-limiting toxicities, and sufficient data to advance to Phase 2b studies. Leadership expressed confidence in the drug's potential for a differentiated product profile in chronic urticaria, supporting continued clinical development momentum.
Investing.com • Fawad Razaqzada